Lipid metabolism characterization in gastric cancer identifies signatures to predict prognostic and therapeutic responses

Abstract

Purpose: Increasing evidence has elucidated the significance of lipid metabolism in predicting therapeutic efficacy. Obviously, a systematic analysis of lipid metabolism characterizations of gastric cancer (GC) needs to be reported.Experimental design: Based on two proposed computational algorithms (TCGA-STAD and GSE84437), the lipid metabolism characterization of 367 GC patients and its systematic relationship with genomic characteristics, clinicopathologic features, and clinical outcomes of GC were analyzed in our study. Differentially expressed genes (DEGs) were identified based on the lipid metabolism cluster. At the same time, we applied single-factor Cox regression and random forest to screen signature genes to construct a prognostic model, namely, the lipid metabolism score (LMscore). Next, we deeply explored the predictive value of the LMscore for GC. To verify the specific changes in lipid metabolism, a total of 90 serum, 30 tumor, and non-tumor adjacent tissues from GC patients, were included for pseudotargeted metabolomics analysis via SCIEX triple quad 5500 LC-MS/MS system.Results: Five lipid metabolism signature genes were identified from a total of 3,104 DEGs. The LMscore could be a prognosticator for survival in different clinicopathological GC cohorts. As well, the LMscore was identified as a predictive biomarker for responses to immunotherapy and chemotherapeutic drugs. Additionally, significant changes in sphingolipid metabolism and sphingolipid molecules were discovered in cancer tissue from GC patients by pseudotargeted metabolomics.Conclusion: In conclusion, multivariate analysis revealed that the LMscore was an independent prognostic biomarker of patient survival and therapeutic responses in GC. Depicting a comprehensive landscape of the characteristics of lipid metabolism may help to provide insights into the pathogenesis of GC, interpret the responses of gastric tumors to therapies, and achieve a better outcome in the treatment of GC. In addition, significant alterations of sphingolipid metabolism and increased levels of sphingolipids, in particular, sphingosine (d16:1) and ceramide, were discovered in GC tissue by lipidome pseudotargeted metabolomics, and most of the sphingolipid molecules have the potential to be diagnostic biomarkers for GC.

Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma

“… 22 Furthermore, lipid metabolic features have been significantly associated with prognosis in bladder cancer, 23 hepatocellular carcinoma, 24 colorectal cancer, 25 and gastric cancer. 26 The characterization of lipid metabolic profiles not only predicts the prognosis of patients with various tumors but also provides a reference for drug development. 27 However, the current drug development targeting lipid metabolism in cancer cells is inadequate.…”

Exosome and lipid metabolism-related genes in pancreatic adenocarcinoma: a prognosis analysis

“…Exosomes, as novel biomarkers for tumors, have been developed for constructing prognostic models in esophageal carcinoma [ 36 ], hepatocellular carcinoma [ 37 ], and pancreatic ductal adenocarcinoma [ 38 ]. Nowadays, increasing studies have found that abnormal lipid metabolism is associated with tumors, and researchers also constructed a prognostic model based on lipid metabolism-related genes to predict patients with gastric [ 39 ] and hepatocellular carcinoma [ 40 ]. Even though exosomes or lipid metabolism genes have been shown to be accurate predictors of tumor prognosis in previous studies, there is still lack of research on EALMRGs as a predictive biomarker for PAAD.…”

Ceramides and Ceramide Synthases in Cancer: Focus on Apoptosis and Autophagy

“…CerS and Ceramides have been implicated in the pathogenesis of various cancers due to their regulatory role in autophagy. Recent reports demonstrated that under starvation condition, Bcl-2 expression inhibits autophagy (13), while C2 and C6-ceramide could trigger autophagy in HT-29 colon carcinoma cell line (8).…”